The use of ICOS inhibitors or IL-21 receptor blockers could provide a more nuanced approach to controlling Tfh-cell activity in RA, especially for patients who do not respond to conventional therapies [53,54]. The gene discussed is IL21R; the disease is rheumatoid arthritis.